Europcr2014 1.2

EuroPCR25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Paris20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

Pharmacological therapy of high thrombus burden in STEMI

Commentary:

Dr James ChongWestmead Hospital, Sydney

Date of preparation May 2014 │BRI001132

Disclaimer

• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.

• These highlights have been suggested by a group of cardiologists who attended EuroPCR 2014, compiled by an external medical writer and sponsored by AstraZeneca. 

• AstraZeneca has obtained permission from EuroPCR, to utilise the selected content for educational purposes.

• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.  Presentations are intended for educational purposes only and do not replace independent professional judgement.

• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.

AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

HEAT-PPCI study: Presented at ACC 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

EuroPCR 2014Paris

20-23 May 2014

• A high thrombus burden is a common challenge in primary PCI.

• Not all cases can be resolved by thrombectomy, for example a high burden at a bifurcation lesion.

• Other patients, including those who are stable and pain-free but have a large thrombus, might be candidates for delayed stenting after initial pharmacological therapy.

• Several studies including DEFER-STEMI and MIMI (presented at ESC 2013) have supported the efficacy and safety of deferred stenting in selected high-risk patients.

Commentary: Dr James Chong